Johannes Jacobus Oosthuizen Form 4 Merck & Co. / Johannes Jacobus Oosthuizen ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Oosthuizen Johannes Jacobus

(Last) (First) (Middle)

MERCK & CO., INC.

126 LINCOLN AVENUE

(Street)

RAHWAY NJ 07065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
President, U.S. Market

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/07/2022		M		14,703	A	$0	26,046.881	D
Common Stock	11/07/2022		M		17,455	A	$0	43,501.881	D
Common Stock	11/07/2022		M		13,540	A	$0	57,041.881	D
Common Stock	11/07/2022		M		7,045	A	$0	64,086.881	D
Common Stock	11/07/2022		S		45,561	D	$99.4706(1)	18,525.881(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$62.07	11/07/2022		M			14,703	05/05/2018(3)	05/04/2027	Common Stock	14,703	$0	0	D
Stock Option (Right to Buy)	$77.62	11/07/2022		M			17,455	05/03/2020(4)	05/02/2029	Common Stock	17,455	$0	0	D
Stock Option (Right to Buy)	$75.36	11/07/2022		M			13,540	05/01/2021(5)	04/30/2030	Common Stock	13,540	$0	6,773	D
Stock Option (Right to Buy)	$73.73	11/07/2022		M			7,045	05/04/2022(6)	05/03/2031	Common Stock	7,045	$0	14,094	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.3700 to $99.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

2. Holdings include shares acquired in dividend reinvestment transactions.

3. The options became exercisable in three equal installments on 5/5/2018, 5/5/2019, and 5/5/2020.

4. The options became exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.

5. The options become exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

6. The options become exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

	/s/ Kelly E. W. Grez, as attorney-in-fact for Johannes Oosthuizen	11/07/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.